ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

Condition

Malignant Mesothelioma

Estimated Enrollment: 300

Age Group: 21 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: CDR0000065639|ALFACELL-P30-302|NCI-V97-1273

Study First Received: November 1, 1999

Last Updated: November 5, 2013

Estimated Primary Completion Date: February 2008

Primary Outcome Measures:

Survival|Objective response|Time to best response|Response duration

Sponsors and Collaborators:

Alfacell|National Cancer Institute (NCI)

Website Link: https://ClinicalTrials.gov/show/NCT00003034